Indo Us Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indo US Biotech Limited's Board of Directors, at its meeting held on August 12, 2025, approved the unaudited standalone financial results for the quarter ended June 30, 2025. The results were submitted to both BSE and NSE along with a limited review report from the statutory auditor, Gautam N Associates, Chartered Accountants. The auditor issued an unmodified review conclusion, stating that nothing came to their attention suggesting the results were not prepared in accordance with applicable Ind-AS standards or contained any material misstatement. The financial figures in the filing were largely illegible due to poor document scan quality, preventing extraction of precise revenue or profit numbers.
Routine quarterly compliance filing with a clean (unqualified) auditor review — no adverse audit flags raised. No immediate material impact on shareholders expected from this disclosure alone, though actual Q1 performance numbers could not be verified due to document quality.